• 1
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1104
  • 2
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917
  • 3
    Van den Ouden D, Hop WC, Schroder FH. Progression and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 13927
  • 4
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 216372
  • 5
    Srigley JR, Amin M, Boccon-Gibod L et al. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl 2005; 216: 819
  • 6
    Fair WR, Betancourt JE. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol 2000; 4: 24150
  • 7
    Gleave M, Goldenberg S, Chin J et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 2003; 169: 690A
  • 8
    Klotz LH, Goldenberg SL, Jewett MA et al.; Canadian Uro-Oncology Group. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 7914
  • 9
    Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 4248
  • 10
    Goldenberg SL, Klotz LH, Srigley J et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 1996; 156: 8737
  • 11
    Aus G, Abrahamsson P, Ahlgren G et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol 1998; 159: 20137
  • 12
    Sokoloff MH, Rinker-Schaeffer CW, Chung LW, Brendler CB. Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells. J Urol 2004; 172: 253944
  • 13
    Laing N, Dahllof B, Hartley-Asp B, Ranganathan S, Tew KD. Interaction of estramustine with tubulin isotypes. Biochemistry 1997; 36: 8718
  • 14
    Ranganathan S, Benetatos C, Colarusso P, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77: 5626
  • 15
    Obasaju C, Hudes G. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15: 52545
  • 16
    Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26 (Suppl. 17): 148
  • 17
    Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 250916
  • 18
    Petrylak DP, MacArthur R, O’Connor J et al. Phase I/II studies of docetaxel. (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999; 26 (Suppl. 17): 2833
  • 19
    Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 70913
  • 20
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 2815
  • 21
    Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 18: 10507
  • 22
    Oh WK, George DJ, Kaufman DS et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001; 28 (Suppl. 15): 404
  • 23
    Hussain M, Smith DC, El-Rayes BF et al. Neoadjuvant docetaxel and extramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61: 77480
  • 24
    Ko Y-L, Dewolf W, Olumi A, Sesterhern IA, Upton M, Bubley GJ. Neoadjuvant chemo-hormonal therapy followed by radical prostatectomy for high risk prostate cancer. Proceedings of ASCO 2002; 21: 162b, Abstract 2465
  • 25
    Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 113842
  • 26
    Fleming ID, Cooper JS, Henson DE et al. eds. AJCC. Cancer Staging Manual, 5th edn. Philadelphia: Lippincott Raven, 1998
  • 27
    Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 64955
  • 28
    DeVere White RW. Pelvic lymph node dissection. In GlenJ ed., Urologic Surgery, Chapt. 55. Philadelphia: Lippincot Co., 1991: 6114
  • 29
    Walsh PC. Anatomic radical retropubic prostatectomy. In WalshPC, RetikAB, VaughnED, WeinAJ eds, Cambell’s Urology, 7th edn. Philadelphia, PA: WB Saunders, 1998: 256588
  • 30
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 110
  • 31
    Ohori M, Kattan MW, Koh H et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171: 18449
  • 32
    Eigl B, Eggener S, Baybik J et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005; 11: 490511
  • 33
    Oudard S, Legrier ME, Boye K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 172934
  • 34
    Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000; 38: 3729
  • 35
    Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995; 154: 144752
  • 36
    Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 38590
  • 37
    Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32 (Suppl. 3): 815
  • 38
    Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 1993; 149: 147881
  • 39
    Humphrey PA, Catalona WJ. Pathological features of prostatic carcinomas detected in a serum prostate specific antigen based screening program. Mod Pathol 1995; 8: 77A
  • 40
    Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3, N0, M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (Suppl.): 6569
  • 41
    Bauer JJ, Sesterhenn I, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996; 156: 15116
  • 42
    Grignon DJ, Caplan R, Sarkar FH et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89: 15865
  • 43
    Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostatic carcinoma. Am J Pathol 1993; 143: 4019
  • 44
    Beer TM, Garzotto M, Lowe BA et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004; 10: 130611
  • 45
    Febbo PG, Richie JP, George DJ et al. Neoadjuvant Docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 523340
  • 46
    Gleave M, Kelly WK. High-risk localized cancer: a case for early chemotherapy. J Clin Oncol 2005; 23: 818691
  • 47
    Eastham JA, Kelly WK, Grossfeld GD, Small EJ; Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62 (Suppl. 1): 5562
  • 48
    Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Intl 2000; 86: 67580